Clinical courses and risk factors for progression of smoldering multiple myeloma: a nationwide cohort study in Japan

DOI Web Site PubMed
  • TAKAMATSU Yasushi
    Division of Medical Oncology, Hematology and Infectious Diseases, Department of Medicine, Fukuoka University
  • MUTA Tsuyoshi
    Department of Hematology, Japan Community Health Care Organization Kyushu Hospital

Bibliographic Information

Other Title
  • 日本におけるくすぶり型骨髄腫の後方視的研究
  • 日本におけるくすぶり型骨髄腫の後方視的研究 : 症候性骨髄腫へのリスク因子を中心に
  • ニホン ニ オケル クスブリ ガタ コツズイシュ ノ コウホウ シテキ ケンキュウ : ショウコウセイ コツズイシュ エ ノ リスク インシ オ チュウシン ニ
  • ―症候性骨髄腫へのリスク因子を中心に―

Search this article

Description

We carried out a cohort study of smoldering multiple myeloma (SMM) in Japan. The clinical data of 207 patients with SMM, median age 69 years (range: 27-90), were collected from 63 institutions. The subtype of myeloma was IgG type in 168, IgA type in 30, and Bence Jones type in 9 patients. At a median follow-up of 39 months, 53% of the patients had progressed to symptomatic MM (within 5 years of the initial diagnosis). As previously described, a serum free light chain ratio >8 or <0.125, along with the number of bone marrow plasma cells being 10% or more and the serum M-protein level being at least 3 g/dl, was a significant predictor of rapid progression. We found that the rate of increase in serum M-protein levels correlated negatively with the risk of progression. The probability of progression within 5 years was 100% in patients whose rate of serum M-protein level increase was 2 mg/dl/day or higher. This indicates that the serum M-protein level increase rate might be a useful predictor of disease progression in SMM.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 56 (8), 1005-1010, 2015

    The Japanese Society of Hematology

Keywords

Details 詳細情報について

Report a problem

Back to top